Inspira Technologies OXY B.H.N. (NASDAQ:IINN) and Accuray (NASDAQ:ARAY) Critical Review

Inspira Technologies OXY B.H.N. (NASDAQ:IINN) and Accuray (NASDAQ:ARAY) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Earnings and Valuation

This table compares Inspira Technologies OXY B.H.N. and Accuray”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspira Technologies OXY B.H.N.	$290,000.00	48.97	-$13.22 million	N/A	N/A
Accuray	$458.51 million	0.07	-$1.59 million	($0.37)	-0.73

Accuray has higher revenue and earnings than Inspira Technologies OXY B.H.N..

Volatility & Risk

Inspira Technologies OXY B.H.N. has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500. Comparatively, Accuray has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500.

Insider & Institutional Ownership

12.7% of Inspira Technologies OXY B.H.N. shares are held by institutional investors. Comparatively, 64.1% of Accuray shares are held by institutional investors. 29.4% of Inspira Technologies OXY B.H.N. shares are held by insiders. Comparatively, 4.4% of Accuray shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Inspira Technologies OXY B.H.N. and Accuray’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A
Accuray	-10.76%	-79.43%	-10.38%

Analyst Ratings

This is a summary of recent recommendations and price targets for Inspira Technologies OXY B.H.N. and Accuray, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspira Technologies OXY B.H.N.	1	0	1	0	2.00
Accuray	1	2	0	0	1.67

Inspira Technologies OXY B.H.N. presently has a consensus price target of $2.00, suggesting a potential upside of 406.33%. Accuray has a consensus price target of $2.00, suggesting a potential upside of 640.74%. Given Accuray’s higher possible upside, analysts plainly believe Accuray is more favorable than Inspira Technologies OXY B.H.N..

Summary

Inspira Technologies OXY B.H.N. beats Accuray on 8 of the 12 factors compared between the two stocks.

About Inspira Technologies OXY B.H.N.

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'annana, Israel.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.